22Q DELETION ( MICRODELETION DIGEORGE SYNDROME) / HEPARIN BLOOD

image not found

NABL Cap Accredited 
The 22q Deletion (Microdeletion DiGeorge Syndrome) Test using heparinized blood at Metropolis Healthcare detects a small missing segment on chromosome 22, known as the 22q11.2 deletion. This genetic change is associated with DiGeorge Syndrome, a condition that can affect the heart, immune system, facial development, and learning abilities. Early detection helps in accurate diagnosis, genetic counseling, and timely intervention. The test provides valuable insights into developmental and congenital abnormalities. Metropolis Healthcare ensures precise results using advanced molecular cytogenetic methods.

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 5,620.00

Sample Type: HEPARIN BLOOD

Fasting Not Required


Booking Procedure:
  1. Technician from Metropolis will be assigned for a free home sample collection after booking confirmation.
  2. Sample will be collected by our technician at your address at given slot.
  3. You will get a payment link in 2 hours. You can make the payment online or pay cash to the technician.
  4. Soft copy reports will be sent to your email address within 24 to 48 hours.

Notes: #0036

Frequently Asked Questions (FAQ's):

1. What is the 22q Deletion (Microdeletion DiGeorge Syndrome) Test using heparinized blood?
This test detects a microdeletion on chromosome 22q11.2, which is responsible for DiGeorge Syndrome, using a heparin-treated blood sample.

2. Why is this test important?
It is crucial for diagnosing DiGeorge Syndrome and related congenital conditions, allowing for early treatment and management.

3. Who should undergo this test?
Newborns, children, or adults showing heart defects, developmental delays, immune issues, or facial abnormalities may be recommended this test.

4. How is the test performed?
At Metropolis Healthcare, a heparinized blood sample is collected and analyzed using FISH or molecular cytogenetic testing for accurate detection of the 22q deletion.

5. What do the results indicate?
A positive result confirms the 22q11.2 deletion, indicating a genetic basis for DiGeorge Syndrome or related disorders.

6. Are there any risks associated with the test?
The test is safe and minimally invasive, involving only a blood sample collection.

7. Why choose Metropolis Healthcare for this test?
Metropolis Healthcare provides high-precision genetic testing, expert interpretation, and state-of-the-art molecular diagnostics to ensure reliable detection of 22q microdeletions.

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab